Literature DB >> 21472491

Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies.

Naoe Yamane1, Zenzaburo Tozuka, Makiko Kusama, Kazuya Maeda, Toshihiko Ikeda, Yuichi Sugiyama.   

Abstract

PURPOSE: To investigate the potency of LC-MS/MS by means of sensitivity and the applicability for cassette dosing in microdose clinical trials.
METHODS: Thirty one top-selling 31 drugs were spiked to human plasma, extracted, and analyzed by LC-MS/MS.
RESULTS: The lower limits of quantification for each drug varied from 0.08 to 50 pg/mL, and were lower than one eighth of the assumed maximum plasma concentration at microdose in all drugs except for losartan, indicating the high performance in acquisition of full pharmacokinetic profiles at microdose. We also succeeded in simultaneous analysis of multiple compounds, assuming a situation of cassette dosing in which multiple drug candidates would be administrated simultaneously.
CONCLUSIONS: Together with the features of LC-MS/MS, such as immediate verification, the utilization of non-radiolabeled drugs and no special facilities, we suppose that LC-MS/MS analysis would be widely applicable in conducting microdose clinical studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472491     DOI: 10.1007/s11095-011-0423-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

Review 1.  Toxicogenomics in predictive toxicology in drug development.

Authors:  Laura Suter; Lee E Babiss; Eric B Wheeldon
Journal:  Chem Biol       Date:  2004-02

2.  Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid in human plasma.

Authors:  Amy Y Yang; Li Sun; Donald G Musson; Jamie J Zhao
Journal:  J Pharm Biomed Anal       Date:  2005-03-17       Impact factor: 3.935

3.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

Authors:  Graham Lappin; Wilhelm Kuhnz; Roeline Jochemsen; Johannes Kneer; Ajai Chaudhary; Berend Oosterhuis; Willem Jan Drijfhout; Malcolm Rowland; R Colin Garner
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

4.  Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma.

Authors:  Naoe Yamane; Tomonori Takami; Zenzaburo Tozuka; Yuichi Sugiyama; Akira Yamazaki; Yuji Kumagai
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

5.  A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.

Authors:  Lee S Zhu; Veniamin N Lapko; Jean W Lee; Yousef J Basir; Chris Kafonek; Richard Olsen; Chad Briscoe
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

Review 6.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.

Authors:  Graham Lappin; R Colin Garner
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

7.  Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.

Authors:  Naoe Yamane; Zenzaburou Tozuka; Yuichi Sugiyama; Toshiko Tanimoto; Akira Yamazaki; Yuji Kumagai
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-19       Impact factor: 3.205

8.  Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects.

Authors:  Yihong Lu; Hongmei Wen; Wei Li; Yumei Chi; Zhengxing Zhang
Journal:  J Chromatogr Sci       Date:  2004 May-Jun       Impact factor: 1.618

9.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

Authors:  C U Kim; W Lew; M A Williams; H Liu; L Zhang; S Swaminathan; N Bischofberger; M S Chen; D B Mendel; C Y Tai; W G Laver; R C Stevens
Journal:  J Am Chem Soc       Date:  1997-01-29       Impact factor: 15.419

10.  The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.

Authors:  J Posner; A Bye; K Dean; A W Peck; P D Whiteman
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more
  7 in total

Review 1.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 2.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

3.  Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.

Authors:  Jianmeng Chen; Charles Flexner; Rosa G Liberman; Paul L Skipper; Nicolette A Louissaint; Steven R Tannenbaum; Craig W Hendrix; Edward J Fuchs
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

Review 4.  Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.

Authors:  T Burt; R J Noveck; D B MacLeod; A T Layton; M Rowland; G Lappin
Journal:  Clin Transl Sci       Date:  2017-04-18       Impact factor: 4.689

Review 5.  Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.

Authors:  T Burt; K Yoshida; G Lappin; L Vuong; C John; S N de Wildt; Y Sugiyama; M Rowland
Journal:  Clin Transl Sci       Date:  2016-03-30       Impact factor: 4.689

Review 6.  Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology.

Authors:  Jeroen Roosendaal; Hilde Rosing; Jos H Beijnen
Journal:  Clin Pharmacol Drug Dev       Date:  2020-06-22

Review 7.  Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?

Authors:  Tal Burt; Ad F Roffel; Oliver Langer; Kirsten Anderson; Joseph DiMasi
Journal:  Clin Transl Sci       Date:  2022-04-21       Impact factor: 4.438

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.